Medical tablets, capsules and caplets flying out of a bottle against a light blue background

People

David Bates

Director of the Centre for Cancer Sciences, Faculty of Medicine & Health Sciences

Personal Details
Teaching and Learning
Research
Publications

Contact

workBioDiscovery Institute
University Park
Nottingham
NG7 2RD
UK
work0115 823 1135
David.Bates@nottingham.ac.uk
http://www.tvbl-nottingham.org

Biography

I am currently Director of the University of Nottingham Centre for Cancer Sciences

I am also Chief Scientific Officer of IsomAb Ltd, a drug discovery company that focuses on developing isoform specific antibodies in areas of high unmet medical need, in particular in cardiovascular disease, cancer and inflammation.

I joined the University of Nottingham as Head of Division of Preclinical Oncology in 2013, and in the same year founded Exonate Ltd, a spin out company based on developing small molecules to regulate mRNA splicing with Prof Steve Harper at University of Bristol, Prof Lucy Donaldson at UoN and Prof Jonathan Morris from UNSW, based on our discovery of new potential drugs for eye disease, cancer and other conditions. Exonate now has its first drug in clinical trial as an eye drop for treatment of diabetic macular oedema, in collaboration with Janssen. I am currently Chair of the SAB for Exonate Ltd.

I completed my PhD in 1992 at the University of London, on how and why patients treated for breast cancer develop swollen arms (lymphoedema). After a year learning molecular genetics of fruit flies at Glasgow University, I spent three years at the University of California at Davis, where I learned and extended a technique to measure how proteins and fluid move across the walls of individual capillaries, by putting tiny glass needles into the smallest blood vessels of the body. At this point I started investigating a new protein called VEGF - or vascular endothelial growth factor. I continued as a lecturer at the University of Leicester from 1996-1998, using novel chemicals, that were part of the process of developing new drugs now used as anti-cancer agents. I developed methods to investigate how VEGF works to cause blood vessels to grow, and moved to the University of Bristol as a British Heart Foundation (BHF) research fellow in the Department of Physiology in 1999.

In 2001 I was awarded a BHF Lectureship, and established the Microvascular Research Laboratories in Bristol. In that year I discovered a new class of VEGF molecules. I was appointed Professor of Microvascular Biology and Medicine in the Department of Physiology and Pharmacology in 2007, where I was responsible for a MSci in Physiology with a year in Industry and the second year BSc Physiology course for 120 undergraduate students per year. My laboratory has discovered how new VEGFs contribute to blindness, diabetes, cancer, lung and heart disease and other conditions, resulting in 10 patent applications and >150 peer reviewed papers in both scientific (Nature Medicine, Cancer Cell etc), and medical journals (Cancer Research, Clinical Cancer Research, Nature Reviews Cancer, etc).

Expertise Summary

My research focusses on how blood vessels grow, and in particular how a protein called Vascular Endothelial Growth Factor (or VEGF) as well as other proteins made by the body can make new vessels form in health and disease. This includes the role of blood vessel growth and permeability in cancers, heart and vascular disease (including atherosclerosis, coronary ischaemia, and peripheral vascular disease), diabetes, (including retinopathy, which causes blindness, nephropathy, which causes kidney failure, vasculopathy which can cause pain and peripheral ischemia, which can lead to ulcers and amputations). Other diseases that I work on include rheumatoid arthritis, renal disease, lymphatic diseases, and the basic causes of oedema (swelling). I also work on cholangiocarcinoma, a cancer of the bile duct, which is common in south east Asia.

I'm particularly interested in alternative splicing.

Teaching Summary

Research Summary

Recent Publications

GRANT ZL, WHITEHEAD L, WONG VHY, HE Z, YAN RY, MILES AR, BENEST AV, BATES DO, PRAHST C, BENTLEY K, BUI BV, SYMONS RC and COULTAS L, 2020. Blocking endothelial apoptosis revascularises the retina in a model of ischemic retinopathy. The Journal of clinical investigation. (In Press.)
MAKHAFOLA, T. J., MBELE, M., YACQUB-USMAN, K., HENDREN, A., HAIGH, D. B., BLACKLEY, Z., MEYER, M., MONGAN, N. P., BATES, D. O. and DLAMINI, Z., 2020. Apoptosis in Cancer Cells Is Induced by Alternative Splicing of hnRNPA2/B1 Through Splicing of Bcl-x, a Mechanism that Can Be Stimulated by an Extract of the South African Medicinal Plant, Cotyledon orbiculata: Front Oncol Front Oncol. 10, 547392
BOONSRI, B., YACQUB-USMAN, K., THINTHARUA, P., MYINT, K. Z., SAE-LAO, T., COLLIER, P., SURIYONPLENGSAENG, C., LARBCHAROENSUB, N., BALASUBRAMANIAN, B., VENKATRAMAN, S., EGBUNIWE, I. U., GOMEZ, D., MUKHERJEE, A., KUMKATE, S., JANVILISRI, T., ZAITOUN, A. M., KUAKPAETOON, T., TOHTONG, R., GRABOWSKA, A. M., BATES, D. O. and WONGPRASERT, K., 2020. Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells: Cancer Res Treat Cancer Res Treat.
HULL, R., MBELE, M., MAKHAFOLA, T., HICKS, C., WANG, S. M., REIS, R. M., MEHROTRA, R., MKHIZE-KWITSHANA, Z., HUSSAIN, S., KIBIKI, G., BATES, D. O. and DLAMINI, Z., 2020. A multinational review: Oesophageal cancer in low to middle-income countries: Oncol Lett Oncol Lett. 20(4), 42

View all publications

Since moving to Nottingham I have led the development of a new undergraduate course in Cancer Sciences, the first of its kind in the UK, and potentially worldwide. The course aims to recruit 35 students from 2019 rising to 75 a year from 2021. I led the course design, planning and resourcing, secured the pump priming from the University (£1.9M) to recruit 7 full time and 4 part time academic staff, leading a team of 5 academics to put this in place. I play a significant role in the curriculum development, and I intend to teach on all three years of the course.

Prior to this I had an extensive undergraduate teaching background, in Bristol, at the University of Leicester, UC Davis, and at St George's Hospital Medical School. I have redesigned modules (cardiovascular, molecular physiology and cell signalling), and implemented new modules (microcirculation), as well as taken responsibility for the running of the 2^nd year course in Physiology in Bristol (120 students per year). The feedback I have had from the students that I have taught, have consistently described the lectures as entertaining, enthusiastic, and clear. I was particularly proud to note feedback on my second year teaching "Best lecturer of the year", particularly as I gave the last three lectures of the year immediately before the exams!

Current Research

I have programs focussing on controlling blood vessel growth in age related macular degeneration, diabetes, cancer of the bile duct, melanoma, basic mechanisms of blood vessel function (including control of vascular permeability and the contribution of the endothelial surface coat - the glycocalyx), and pre-eclampsia

GRANT ZL, WHITEHEAD L, WONG VHY, HE Z, YAN RY, MILES AR, BENEST AV, BATES DO, PRAHST C, BENTLEY K, BUI BV, SYMONS RC and COULTAS L, 2020. Blocking endothelial apoptosis revascularises the retina in a model of ischemic retinopathy. The Journal of clinical investigation. (In Press.)
MAKHAFOLA, T. J., MBELE, M., YACQUB-USMAN, K., HENDREN, A., HAIGH, D. B., BLACKLEY, Z., MEYER, M., MONGAN, N. P., BATES, D. O. and DLAMINI, Z., 2020. Apoptosis in Cancer Cells Is Induced by Alternative Splicing of hnRNPA2/B1 Through Splicing of Bcl-x, a Mechanism that Can Be Stimulated by an Extract of the South African Medicinal Plant, Cotyledon orbiculata: Front Oncol Front Oncol. 10, 547392
BOONSRI, B., YACQUB-USMAN, K., THINTHARUA, P., MYINT, K. Z., SAE-LAO, T., COLLIER, P., SURIYONPLENGSAENG, C., LARBCHAROENSUB, N., BALASUBRAMANIAN, B., VENKATRAMAN, S., EGBUNIWE, I. U., GOMEZ, D., MUKHERJEE, A., KUMKATE, S., JANVILISRI, T., ZAITOUN, A. M., KUAKPAETOON, T., TOHTONG, R., GRABOWSKA, A. M., BATES, D. O. and WONGPRASERT, K., 2020. Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells: Cancer Res Treat Cancer Res Treat.
HULL, R., MBELE, M., MAKHAFOLA, T., HICKS, C., WANG, S. M., REIS, R. M., MEHROTRA, R., MKHIZE-KWITSHANA, Z., HUSSAIN, S., KIBIKI, G., BATES, D. O. and DLAMINI, Z., 2020. A multinational review: Oesophageal cancer in low to middle-income countries: Oncol Lett Oncol Lett. 20(4), 42
HULL, R., MBELE, M., MAKHAFOLA, T., HICKS, C., WANG, S. M., REIS, R. M., MEHROTRA, R., MKHIZE-KWITSHANA, Z., KIBIKI, G., BATES, D. O. and DLAMINI, Z., 2020. Cervical cancer in low and middle-income countries: Oncol Lett Oncol Lett. 20(3), 2058-2074
KETELAAR, M. E., PORTELLI, M. A., DIJK, F. N., SHRINE, N., FAIZ, A., VERMEULEN, C. J., XU, C. J., HANKINSON, J., BHAKER, S., HENRY, A. P., BILLINGTON, C. K., SHAW, D. E., JOHNSON, S. R., BENEST, A. V., PANG, V., BATES, D. O., POGSON, Z. E. K., FOGARTY, A., MCKEEVER, T. M., SINGAPURI, A., HEANEY, L. G., MANSUR, A. H., CHAUDHURI, R., THOMSON, N. C., HOLLOWAY, J. W., LOCKETT, G. A., HOWARTH, P. H., NIVEN, R., SIMPSON, A., TOBIN, M. D., HALL, I. P., WAIN, L. V., BLAKEY, J. D., BRIGHTLING, C. E., OBEIDAT, M., SIN, D. D., NICKLE, D. C., BOSSE, Y., VONK, J. M., VAN DEN BERGE, M., KOPPELMAN, G. H., SAYERS, I. and NAWIJN, M. C., 2020. Phenotypic and functional translation of IL33 genetics in asthma: J Allergy Clin Immunol J Allergy Clin Immunol.
ALLEN, C. L., MALHI, N. K., WHATMORE, J. L., BATES, D. O. and ARKILL, K. P., 2020. Non-invasive measurement of retinal permeability in a diabetic rat model: Microcirculation Microcirculation. 27(6), e12623
WILSON, D. H., JARMAN, E. J., MELLIN, R. P., WILSON, M. L., WADDELL, S. H., TSOKKOU, P., YOUNGER, N. T., RAVEN, A., BHALLA, S. R., NOLL, A. T. R., OLDE DAMINK, S. W., SCHAAP, F. G., CHEN, P., BATES, D. O., BANALES, J. M., DEAN, C. H., HENDERSON, D. J., SANSOM, O. J., KENDALL, T. J. and BOULTER, L., 2020. Non-canonical Wnt signalling regulates scarring in biliary disease via the planar cell polarity receptors: Nat Commun Nat Commun. 11(1), 445
OWEN-WOODS, C., JOULIA, R., BARKAWAY, A., ROLAS, L., MA, B., NOTTEBAUM, A. F., ARKILL, K. P., STEIN, M., GIRBL, T., GOLDING, M., BATES, D. O., VESTWEBER, D., VOISIN, M. B. and NOURSHARGH, S., 2020. Local microvascular leakage promotes trafficking of activated neutrophils to remote organs: J Clin Invest Journal of Clinical Investigation. 130(5), 2301-2318
STEVENS, M., STAR, E., LEE, M., INNES, E., LI, L., BOWLER, E., HARPER, S., BATES, D. O. and OLTEAN, S., 2019. The VEGF-A exon 8 splicing-sensitive fluorescent reporter mouse is a novel tool to assess the effects of splicing regulatory compounds in vivo: RNA Biol RNA Biol. 16(12), 1672-1681
MACHADO, M. J. C., BOARDMAN, R., RIU, F., EMANUELI, C., BENEST, A. V. and BATES, D. O., 2019. Enhanced notch signaling modulates unproductive revascularization in response to nitric oxide-angiopoietin signaling in a mouse model of peripheral ischemia: Microcirculation Microcirculation. 26(6), e12549
LI, N., BABAEI-JADIDI, R., LORENZI, F., SPENCER-DENE, B., CLARKE, P., DOMINGO, E., TULCHINSKY, E., VRIES, R. G. J., KERR, D., PAN, Y., HE, Y., BATES, D. O., TOMLINSON, I., CLEVERS, H. and NATERI, A. S., 2019. An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance: Oncogenesis Oncogenesis. 8(3), 13
BOARDMAN, R., PANG, V., MALHI, N., LYNCH, A. P., LEACH, L., BENEST, A. V., BATES, D. O. and MACHADO, M. J. C., 2019. Activation of Notch signaling by soluble Dll4 decreases vascular permeability via a cAMP/PKA-dependent pathway: Am J Physiol Heart Circ Physiol Am J Physiol Heart Circ Physiol. 316(5), H1065-H1075
ONIONS, K. L., GAMEZ, M., BUCKNER, N. R., BAKER, S. L., BETTERIDGE, K. B., DESIDERI, S., DALLYN, B. P., RAMNATH, R. D., NEAL, C. R., FARMER, L. K., MATHIESON, P. W., GNUDI, L., ALITALO, K., BATES, D. O., SALMON, A. H. J., WELSH, G. I., SATCHELL, S. C. and FOSTER, R. R., 2019. VEGFC Reduces Glomerular Albumin Permeability and Protects Against Alterations in VEGF Receptor Expression in Diabetic Nephropathy: Diabetes Diabetes. 68(1), 172-187
BATES, D. O., BEAZLEY-LONG, N., BENEST, A. V., YE, X., VED, N., HULSE, R. P., BARRATT, S., MACHADO, M. J., DONALDSON, L. F., HARPER, S. J., PEIRIS-PAGES, M., TORTONESE, D. J., OLTEAN, S. and FOSTER, R. R., 2018. Physiological Role of Vascular Endothelial Growth Factors as Homeostatic Regulators: Compr Physiol Compr Physiol. 8(3), 955-979
BESTALL, S. M., HULSE, R. P., BLACKLEY, Z., SWIFT, M., VED, N., PATON, K., BEAZLEY-LONG, N., BATES, D. O. and DONALDSON, L. F., 2018. Sensory neuronal sensitisation occurs through HMGB-1/ RAGE and TRPV1 in high glucose conditions: J Cell Sci J Cell Sci.
NEAL, C. R., ARKILL, K., BELL, J. S., BETTERIDGE, K. B., BATES, D. O., WINLOVE, C. P., SALMON, A. H. and HARPER, S. J., 2018. Novel Haemodynamic Structures in the Human Glomerulus: Am J Physiol Renal Physiol Am J Physiol Renal Physiol.
VED, N., DA VITORIA LOBO, M. E., BESTALL, S. M., L. VIDUEIRA C, BEAZLEY-LONG, N., BALLMER-HOFER, K., HIRASHIMA, M., BATES, D. O., DONALDSON, L. F. and HULSE, R. P., 2018. Diabetes-induced microvascular complications at the level of the spinal cord; a contributing factor in diabetic neuropathic pain: J Physiol J Physiol.
NOWAK-SLIWINSKA, P., ALITALO, K., ALLEN, E., ANISIMOV, A., APLIN, A. C., AUERBACH, R., AUGUSTIN, H. G., BATES, D. O., VAN BEIJNUM, J. R., BENDER, R. H. F., BERGERS, G., BIKFALVI, A., BISCHOFF, J., BOCK, B. C., BROOKS, P. C., BUSSOLINO, F., CAKIR, B., CARMELIET, P., CASTRANOVA, D., CIMPEAN, A. M., CLEAVER, O., COUKOS, G., DAVIS, G. E., DE PALMA, M., DIMBERG, A., DINGS, R. P. M., DJONOV, V., DUDLEY, A. C., DUFTON, N. P., FENDT, S. M., FERRARA, N., FRUTTIGER, M., FUKUMURA, D., GHESQUIERE, B., GONG, Y., GRIFFIN, R. J., HARRIS, A. L., HUGHES, C. C. W., HULTGREN, N. W., IRUELA-ARISPE, M. L., IRVING, M., JAIN, R. K., KALLURI, R., KALUCKA, J., KERBEL, R. S., KITAJEWSKI, J., KLAASSEN, I., KLEINMANN, H. K., KOOLWIJK, P., KUCZYNSKI, E., KWAK, B. R., MARIEN, K., MELERO-MARTIN, J. M., MUNN, L. L., NICOSIA, R. F., NOEL, A., NURRO, J., OLSSON, A. K., PETROVA, T. V., PIETRAS, K., PILI, R., POLLARD, J. W., POST, M. J., QUAX, P. H. A., RABINOVICH, G. A., RAICA, M., RANDI, A. M., RIBATTI, D., RUEGG, C., SCHLINGEMANN, R. O., SCHULTE-MERKER, S., SMITH, L. E. H., SONG, J. W., STACKER, S. A., STALIN, J., STRATMAN, A. N., VAN DE VELDE, M., VAN HINSBERGH, V. W. M., VERMEULEN, P. B., WALTENBERGER, J., WEINSTEIN, B. M., XIN, H., YETKIN-ARIK, B., YLA-HERTTUALA, S., YODER, M. C. and GRIFFIOEN, A. W., 2018. Consensus guidelines for the use and interpretation of angiogenesis assays: Angiogenesis Angiogenesis.
STEVENS, M., NEAL, C. R., SALMON, A. H. J., BATES, D. O., HARPER, S. J. and OLTEAN, S., 2018. Vascular Endothelial Growth Factor-A165b Restores Normal Glomerular Water Permeability in a Diphtheria-Toxin Mouse Model of Glomerular Injury: Nephron Nephron. 139(1), 51-62
TZELEPIS, K., DE BRAEKELEER, E., ASPRIS, D., BARBIERI, I., VIJAYABASKAR, M. S., LIU, W. H., GOZDECKA, M., METZAKOPIAN, E., TOOP, H. D., DUDEK, M., ROBSON, S. C., HERMIDA-PRADO, F., YANG, Y. H., BABAEI-JADIDI, R., GARYFALLOS, D. A., PONSTINGL, H., DIAS, J. M. L., GALLIPOLI, P., SEILER, M., BUONAMICI, S., VICK, B., BANNISTER, A. J., RAD, R., PRINJHA, R. K., MARIONI, J. C., HUNTLY, B., BATSON, J., MORRIS, J. C., PINA, C., BRADLEY, A., JEREMIAS, I., BATES, D. O., YUSA, K., KOUZARIDES, T. and VASSILIOU, G. S., 2018. SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4: Nat Commun Nat Commun. 9(1), 5378
DESCAMPS, B., SAIF, J., BENEST, A. V., BIGLINO, G., BATES, D. O., CHAMORRO-JORGANES, A. and EMANUELI, C., 2018. BDNF (Brain-Derived Neurotrophic Factor) Promotes Embryonic Stem Cells Differentiation to Endothelial Cells Via a Molecular Pathway, Including MicroRNA-214, EZH2 (Enhancer of Zeste Homolog 2), and eNOS (Endothelial Nitric Oxide Synthase): Arterioscler Thromb Vasc Biol Arteriosclerosis Thrombosis and Vascular Biology. 38(9), 2117-2125
VED N, HULSE RP, BESTALL SM, DONALDSON LF, BAINBRIDGE JW and BATES DO, 2017. Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina. Clinical science (London, England : 1979). (In Press.)
BARRATT SL, BLYTHE T, JARRETT C, OURRADI K, SHELLEY-FRASER G, DAY MJ, QIU Y, HARPER S, MAHER TM, OLTEAN S, HAMES TJ, SCOTTON CJ, WELSH GI, BATES DO and MILLAR AB, 2017. Differential Expression of VEGF-Axxx Isoforms is Critical for Development of Pulmonary Fibrosis. American journal of respiratory and critical care medicine. (In Press.)
PRUSZKO M, MILANO E, FORCATO M, DONZELLI S, GANCI F, DI AGOSTINO S, DE PANFILIS S, FAZI F, BATES DO, BICCIATO S, ZYLICZ M, ZYLICZ A, BLANDINO G and FONTEMAGGI G, 2017. The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1. EMBO reports. (In Press.)
MORTARA L, BENEST AV, BATES DO and NOONAN DM, 2017. Can the co-dependence of the immune system and angiogenesis facilitate pharmacological targeting of tumours? Current opinion in pharmacology. 35, 66-74 (In Press.)
STEVENS M, NEAL CR, SALMON AHJ, BATES DO, HARPER SJ and OLTEAN S, 2017. VEGF-A165 b protects against proteinuria in a mouse model with progressive depletion of all endogenous VEGF-A splice isoforms from the kidney. The Journal of physiology. (In Press.)
SAE-LAO T, TOHTONG R, BATES DO and WONGPRASERT K, 2017. Sulfated Galactans from Red Seaweed Gracilaria fisheri Target EGFR and Inhibit Cholangiocarcinoma Cell Proliferation. The American journal of Chinese medicine. 45(3), 615-633
CASTLE-MILLER J, BATES DO and TORTONESE DJ, 2017. Mechanisms regulating angiogenesis underlie seasonal control of pituitary function. Proceedings of the National Academy of Sciences of the United States of America. 114(12), E2514-E2523
BATSON J, TOOP HD, REDONDO C, BABAEI-JADIDI R, CHAIKUAD A, WEARMOUTH SF, GIBBONS B, ALLEN C, TALLANT C, ZHANG J, DU C, HANCOX JC, HAWTREY T, DA ROCHA J, GRIFFITH R, KNAPP S, BATES DO and MORRIS JC, 2017. Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease. ACS chemical biology. 12(3), 825-832
BENEST AV and BATES DO, 2016. Measurement of Angiogenesis, Arteriolargenesis, and Lymphangiogenesis Phenotypes by Use of Two-Dimensional Mesenteric Angiogenesis Assay. Methods in molecular biology (Clifton, N.J.). 1430, 345-54
DLAMINI Z, MBITA Z and BATES DO, 2016. Erratum to: South African Herbal Extracts as Potential Chemopreventive Agents: Screening for Anticancer Splicing Activity. Methods in molecular biology (Clifton, N.J.). 1379, E1
YE X, ABOU-RAYYAH Y, BISCHOFF J, RITCHIE A, SEBIRE NJ, WATTS P, CHURCHILL AJ and BATES DO, 2016. Altered ratios of pro- and anti-angiogenic VEGF-A variants and pericyte expression of DLL4 disrupt vascular maturation in infantile haemangioma. The Journal of pathology. 239(2), 139-51
GAMMONS MV and BATES DO, 2016. Models of Oxygen Induced Retinopathy in Rodents. Methods in molecular biology (Clifton, N.J.). 1430, 317-32
HULSE RP, DRAKE RA, BATES DO and DONALDSON LF, 2016. The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain. Neurobiology of disease. 96, 186-200
BATES DO, MORRIS JC, OLTEAN S and DONALDSON LF, 2016. Pharmacology of Modulators of Alternative Splicing. Pharmacological reviews. 69(1), 63-79
STONE OA, CARTER JG, LIN PC, PALEOLOG E, MACHADO MJ and BATES DO, 2016. Differential regulation of blood flow-induced neovascularization and mural cell recruitment by vascular endothelial growth factor and angiopoietin signalling. The Journal of physiology. 595(5), 1575-1591
LOBO DP, WEMYSS AM, SMITH DJ, STRAUBE A, BETTERIDGE KB, SALMON AH, FOSTER RR, ELHEGNI HE, SATCHELL SC, LITTLE HA, PACHECO-GÓMEZ R, SIMMONS MJ, HICKS MR, BATES DO, RODGER A, DAFFORN TR and ARKILL KP, 2016. Direct detection and measurement of wall shear stress using a filamentous bio-nanoparticle. Nano research. 8(10), 3307-3315
DE BROT S, NTEKIM A, CARDENAS R, JAMES V, ALLEGRUCCI C, HEERY D, BATES DO, ODUM N, PERSSON JL and MONGAN NP, 2015. Regulation of vascular endothelial growth factor (VEGF) in prostate cancer. Endocrine-related cancer. 22(3), R107-23
HULSE RP, BEAZLEY-LONG N, VED N, BESTALL SM, RIAZ H, SINGHAL P, BALLMER HOFER K, HARPER SJ, BATES DO and DONALDSON LF, 2015. Vascular endothelial growth factor-A165b prevents diabetic neuropathic pain and sensory neuronal degeneration. Clinical science (London, England : 1979). 129(8), 741-56
OLTEAN S, QIU Y, FERGUSON JK, STEVENS M, NEAL C, RUSSELL A, KAURA A, ARKILL KP, HARRIS K, SYMONDS C, LACEY K, WIJEYARATNE L, GAMMONS M, WYLIE E, HULSE RP, ALSOP C, COPE G, DAMODARAN G, BETTERIDGE KB, RAMNATH R, SATCHELL SC, FOSTER RR, BALLMER-HOFER K, DONALDSON LF, BARRATT J, BAELDE HJ, HARPER SJ, BATES DO and SALMON AHJ, 2015. Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy. Journal of the American Society of Nephrology : JASN. 26(8), 1889-1904
BEAZLEY-LONG N, GASTON K, HARPER SJ, ORLANDO A and BATES DO, 2015. Novel mechanisms of resistance to vemurafenib in melanoma - V600E B-Raf reversion and switching VEGF-A splice isoform expression. American journal of cancer research. 5(1), 433-41
DLAMINI Z, MBITA Z and BATES DO, 2015. South African Herbal Extracts as Potential Chemopreventive Agents: Screening for Anticancer Splicing Activity. Methods in molecular biology (Clifton, N.J.). 1379, 201-11
VIEIRA GC, CHOCKALINGAM S, MELEGH Z, GREENHOUGH A, MALIK S, SZEMES M, PARK JH, KAIDI A, ZHOU L, CATCHPOOLE D, MORGAN R, BATES DO, GABB PD and MALIK K, 2015. LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/β-catenin signalling in neuroblastoma. Oncotarget. 6(37), 40053-67
BUNNI J, SHELLEY-FRASER G, STEVENSON K, OLTEAN S, SALMON A, HARPER SJ, CARTER JG and BATES DO, 2015. Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios. American journal of cancer research. 5(6), 2083-9
WU WK, GEORGIADIS A, COPLAND DA, LIYANAGE S, LUHMANN UF, ROBBIE SJ, LIU J, WU J, BAINBRIDGE JW, BATES DO, ALI RR, NICHOLSON LB and DICK AD, 2015. IL-4 regulates specific Arg-1(+) macrophage sFlt-1-mediated inhibition of angiogenesis. The American journal of pathology. 185(8), 2324-35
HULSE RP, BEAZLEY-LONG N, HUA J, KENNEDY H, PRAGER J, BEVAN H, QIU Y, FERNANDES ES, GAMMONS MV, BALLMER-HOFER K, GITTENBERGER DE GROOT AC, CHURCHILL AJ, HARPER SJ, BRAIN SD, BATES DO and DONALDSON LF, 2014. Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia. Neurobiology of disease.
ARKILL, KENTON P., QVORTRUP, KLAUS, STARBORG, TOBIAS, MANTELL, JUDITH M., KNUPP, CARLO, MICHEL, C. CHARLES, HARPER, STEVE J., SALMON, ANDY HJ, SQUIRE, JOHN M., BATES, DAVE O. and NEAL, CHRIS R., 2014. Resolution of the three dimensional structure of components of the glomerular filtration barrier BMC NEPHROLOGY. 15,
MAVROU A, BRAKSPEAR K, HAMDOLLAH-ZADEH M, DAMODARAN G, BABAEI-JADIDI R, OXLEY J, GILLATT DA, LADOMERY MR, HARPER SJ, BATES DO and OLTEAN S, 2014. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene. 34(33), 4311-9
CARTER JG, GAMMONS MV, DAMODARAN G, CHURCHILL AJ, HARPER SJ and BATES DO, 2014. The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy. Angiogenesis. 18(1), 23-30
KIKUCHI R, NAKAMURA K, MACLAUCHLAN S, NGO DT, SHIMIZU I, FUSTER JJ, KATANASAKA Y, YOSHIDA S, QIU Y, YAMAGUCHI TP, MATSUSHITA T, MUROHARA T, GOKCE N, BATES DO, HAMBURG NM and WALSH K, 2014. An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease. Nature medicine. 20(12), 1464-71
HAMDOLLAH ZADEH MA, AMIN EM, HOAREAU-AVEILLA C, DOMINGO E, SYMONDS KE, YE X, HEESOM KJ, SALMON A, D'SILVA O, BETTERIDGE KB, WILLIAMS AC, KERR DJ, SALMON AH, OLTEAN S, MIDGLEY RS, LADOMERY MR, HARPER SJ, VAREY AH and BATES DO, 2014. Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance. Molecular oncology. 9(1), 167-78
BILLS VL, HAMDOLLAH-ZADEH M, SOOTHILL PW, HARPER SJ and BATES DO, 2014. The role of VEGF-A165b in trophoblast survival. BMC pregnancy and childbirth. 14, 278
NGO DT, FARB MG, KIKUCHI R, KARKI S, TIWARI S, BIGORNIA SJ, BATES DO, LAVALLEY MP, HAMBURG NM, VITA JA, HESS DT, WALSH K and GOKCE N, 2014. Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity. Circulation. 130(13), 1072-80
THICHANPIANG P, HARPER SJ, WONGPRASERT K and BATES DO, 2014. TNF-α-induced ICAM-1 expression and monocyte adhesion in human RPE cells is mediated in part through autocrine VEGF stimulation. Molecular vision. 20, 781-9
GAMMONS MV, LUCAS R, DEAN R, COUPLAND SE, OLTEAN S and BATES DO, 2014. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. British journal of cancer. 111(3), 477-85
ARKILL KP, QVORTRUP K, STARBORG T, MANTELL JM, KNUPP C, MICHEL CC, HARPER SJ, SALMON AH, SQUIRE JM, BATES DO and NEAL CR, 2014. Resolution of the three dimensional structure of components of the glomerular filtration barrier. BMC nephrology. 15, 24
DELCOMBEL R, JANSSEN L, VASSY R, GAMMONS M, HADDAD O, RICHARD B, LETOURNEUR D, BATES D, HENDRICKS C, WALTENBERGER J, STARZEC A, SOUNNI NE, NOËL A, DEROANNE C, LAMBERT C and COLIGE A, 2013. New prospects in the roles of the C-terminal domains of VEGF-A and their cooperation for ligand binding, cellular signaling and vessels formation. Angiogenesis. 16(2), 353-71
BEAZLEY-LONG, N., HUA, J., JEHLE, T., HULSE, R.P., DERSCH, R., LEHRLING, C., BEVAN, H., QIU, Y., LAGRÈZE, W.A., WYNICK, D., CHURCHILL, A.J., KEHOE, P., HARPER, S.J., BATES, D.O. and DONALDSON, L.F., 2013. VEGF-A₁₆₅b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro The American Journal of Pathology. 183(3), 918-929
OLTEAN S and BATES DO, 2013. Hallmarks of alternative splicing in cancer. Oncogene. 33(46), 5311-8
BATES DO, MAVROU A, QIU Y, CARTER JG, HAMDOLLAH-ZADEH M, BARRATT S, GAMMONS MV, MILLAR AB, SALMON AH, OLTEAN S and HARPER SJ, 2013. Detection of VEGF-A(xxx)b isoforms in human tissues. PloS one. 8(7), e68399
GAMMONS MV, FEDOROV O, IVISON D, DU C, CLARK T, HOPKINS C, HAGIWARA M, DICK AD, COX R, HARPER SJ, HANCOX JC, KNAPP S and BATES DO, 2013. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Investigative ophthalmology & visual science. 54(9), 6052-62
GAMMONS MV, DICK AD, HARPER SJ and BATES DO, 2013. SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Investigative ophthalmology & visual science. 54(8), 5797-806
ARKILL, K. P., NEAL, C. R., MANTELL, J. M., MICHEL, C. C., QVORTRUP, K., ROSTGAARD, J., BATES, D. O., KNUPP, C. and SQUIRE, J. M., 2012. 3D reconstruction of the glycocalyx structure in mammalian capillaries using electron tomography: Microcirculation Microcirculation. 19(4), 343-51
BATES, D.O., CATALANO, P.J., SYMONDS, K.E., VAREY, A.H.R., RAMANI, P., O'DWYER, P.J., GIANTONIO, B.J., MEROPOL, N.J., BENSON, A.B. and HARPER, S.J., 2012. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab Clinical Cancer Research. 18(22), 6384-6391
OLTEAN, S., NEAL, C. R., MAVROU, A., PATEL, P., AHAD, T., ALSOP, C., LEE, T., SISON, K., QIU, Y., HARPER, S. J., BATES, D. O. and SALMON, A. H., 2012. VEGF165b overexpression restores normal glomerular water permeability in VEGF164-overexpressing adult mice: Am J Physiol Renal Physiol Am J Physiol Renal Physiol. 303(7), F1026-36
QIU, Y., SEAGER, M., OSMAN, A., CASTLE-MILLER, J., BEVAN, H., TORTONESE, D. J., MURPHY, D., HARPER, S. J., FRASER, H. M., DONALDSON, L. F. and BATES, D. O., 2012. Ovarian VEGF(165)b expression regulates follicular development, corpus luteum function and fertility: Reproduction Reproduction. 143(4), 501-11
SALMON, A.H.J., FERGUSON, J.K., BURFORD, J.L., GEVORGYAN, H., NAKANO, D., HARPER, S.J., BATES, D.O. and PETI-PETERDI, J., 2012. Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction Journal of the American Society of Nephrology. 23(8), 1339-1350
OLTEAN S, GAMMONS M, HULSE R, HAMDOLLAH-ZADEH M, MAVROU A, DONALDSON L, SALMON AH, HARPER SJ, LADOMERY MR and BATES DO, 2012. SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases. Biochemical Society transactions. 40(4), 831-5
BATES DO, CATALANO PJ, SYMONDS KE, VAREY AH, RAMANI P, O'DWYER PJ, GIANTONIO BJ, MEROPOL NJ, BENSON AB and HARPER SJ, 2012. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(22), 6384-91
OLTEAN S, NEAL CR, MAVROU A, PATEL P, AHAD T, ALSOP C, LEE T, SISON K, QIU Y, HARPER SJ, BATES DO and SALMON AH, 2012. VEGF165b overexpression restores normal glomerular water permeability in VEGF164-overexpressing adult mice. American journal of physiology. Renal physiology. 303(7), F1026-36
SALMON AH, FERGUSON JK, BURFORD JL, GEVORGYAN H, NAKANO D, HARPER SJ, BATES DO and PETI-PETERDI J, 2012. Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. Journal of the American Society of Nephrology : JASN. 23(8), 1339-50
ARKILL KP, NEAL CR, MANTELL JM, MICHEL CC, QVORTRUP K, ROSTGAARD J, BATES DO, KNUPP C and SQUIRE JM, 2012. 3D reconstruction of the glycocalyx structure in mammalian capillaries using electron tomography. Microcirculation (New York, N.Y. : 1994). 19(4), 343-51
WOOLARD, J., VOUSDEN, W., MOSS, S.J., KRISHNAKUMAR, A., GAMMONS, M.V.R., NOWAK, D.G., DIXON, N., MICKLEFIELD, J., SPANNHOFF, A., BEDFORD, M.T., GREGORY, M.A., MARTIN, C.J., LEADLAY, P.F., ZHANG, M.Q., HARPER, S.J., BATES, D.O. and WILKINSON, B., 2011. Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms Chemical Science. 2(2), 273-278
AMIN, E.M., OLTEAN, S., HUA, J., GAMMONS, M.V., HAMDOLLAH-ZADEH, M., WELSH, G.I., CHEUNG, M.K., NI, L., KASE, S., RENNEL, E.S., SYMONDS, K.E., NOWAK, D.G., ROYER-POKORA, B., SALEEM, M.A., HAGIWARA, M., SCHUMACHER, V.A., HARPER, S.J., HINTON, D.R., BATES, D.O. and LADOMERY, M.R., 2011. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing Cancer Cell. 20(6), 768-780
BATES, D. O., 2011. An unexpected tail of VEGF and PlGF in pre-eclampsia: Biochem Soc Trans Biochem Soc Trans. 39(6), 1576-82
BILLS, V. L., SALMON, A. H., HARPER, S. J., OVERTON, T. G., NEAL, C. R., JEFFERY, B., SOOTHILL, P. W. and BATES, D. O., 2011. Impaired vascular permeability regulation caused by the VEGF(1)(6)(5)b splice variant in pre-eclampsia: BJOG BJOG. 118(10), 1253-61
CARTER, J. G., CHERRY, J., WILLIAMS, K., TURNER, S., BATES, D. O. and CHURCHILL, A. J., 2011. Splicing factor polymorphisms, the control of VEGF isoforms and association with angiogenic eye disease: Curr Eye Res Curr Eye Res. 36(4), 328-35
EMMETT, M. S., LANATI, S., DUNN, D. B., STONE, O. A. and BATES, D. O., 2011. CCR7 mediates directed growth of melanomas towards lymphatics: Microcirculation Microcirculation. 18(3), 172-82
RENNEL, E. S., REGULA, J. T., HARPER, S. J., THOMAS, M., KLEIN, C. and BATES, D. O., 2011. A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis: Microcirculation Microcirculation. 18(7), 598-607
NOWAK, D.G., AMIN, E.M., RENNEL, E.S., HOAREAU-AVEILLA, C., GAMMONS, M., DAMODORAN, G., HAGIWARA, M., HARPER, S.J., WOOLARD, J., LADOMERY, M.R. and BATES, D.O., 2010. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis Journal of Biological Chemistry. 285(8), 5532-5540
BATES, D. O., 2010. Vascular endothelial growth factors and vascular permeability: Cardiovasc Res Cardiovasc Res. 87(2), 262-71
BATES, D. O., 2010. An interstitial hypothesis for breast cancer related lymphoedema: Pathophysiology Pathophysiology. 17(4), 289-94
CRISTOFARO, B., STONE, O. A., CAPORALI, A., DAWBARN, D., IERONIMAKIS, N., REYES, M., MADEDDU, P., BATES, D. O. and EMANUELI, C., 2010. Neurotrophin-3 is a novel angiogenic factor capable of therapeutic neovascularization in a mouse model of limb ischemia: Arterioscler Thromb Vasc Biol Arterioscler Thromb Vasc Biol. 30(6), 1143-50
EMMETT, M. S., SYMONDS, K. E., RIGBY, H., COOK, M. G., PRICE, R., METCALFE, C., ORLANDO, A. and BATES, D. O., 2010. Prediction of melanoma metastasis by the Shields index based on lymphatic vessel density: BMC Cancer BMC Cancer. 10, 208
FOSTER, R. R., WELSH, G. I., SATCHELL, S. C., MARLOW, R. D., WHERLOCK, M. D., PONS, D., MATHIESON, P. W., BATES, D. O. and SALEEM, M. A., 2010. Functional distinctions in cytosolic calcium regulation between cells of the glomerular filtration barrier: Cell Calcium Cell Calcium. 48(1), 44-53
HARPER, S. J. and BATES, D. O., 2010. Glomerular filtration barrier and molecular segregation: guilty as charged?: J Am Soc Nephrol J Am Soc Nephrol. 21(12), 2009-11
HUA, J., SPEE, C., KASE, S., RENNEL, E. S., MAGNUSSEN, A. L., QIU, Y., VAREY, A., DHAYADE, S., CHURCHILL, A. J., HARPER, S. J., BATES, D. O. and HINTON, D. R., 2010. Recombinant human VEGF165b inhibits experimental choroidal neovascularization: Invest Ophthalmol Vis Sci Invest Ophthalmol Vis Sci. 51(8), 4282-8
LANATI, S., DUNN, D.B., ROUSSIGNE, M., EMMETT, M.S., CARRIERE, V., JULLIEN, D., BUDGE, J., FRYER, J., ERARD, M., CAILLER, F., GIRARD, J.P. and BATES, D.O., 2010. Chemotrap-1: an engineered soluble receptor that blocks chemokine-induced migration of metastatic cancer cells in vivo Cancer Research. 70(20), 8138-8148
MAGNUSSEN, A. L., RENNEL, E. S., HUA, J., BEVAN, H. S., BEAZLEY LONG, N., LEHRLING, C., GAMMONS, M., FLOEGE, J., HARPER, S. J., AGOSTINI, H. T., BATES, D. O. and CHURCHILL, A. J., 2010. VEGF-A165b is cytoprotective and antiangiogenic in the retina: Invest Ophthalmol Vis Sci Invest Ophthalmol Vis Sci. 51(8), 4273-81
PEIRIS-PAGES, M., HARPER, S. J., BATES, D. O. and RAMANI, P., 2010. Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth: J Pathol J Pathol. 222(2), 138-47
QIU, Y., FERGUSON, J., OLTEAN, S., NEAL, C. R., KAURA, A., BEVAN, H., WOOD, E., SAGE, L. M., LANATI, S., NOWAK, D. G., SALMON, A. H., BATES, D. and HARPER, S. J., 2010. Overexpression of VEGF165b in podocytes reduces glomerular permeability: J Am Soc Nephrol J Am Soc Nephrol. 21(9), 1498-509
VARET, J., DOUGLAS, S. K., GILMARTIN, L., MEDFORD, A. R., BATES, D. O., HARPER, S. J. and MILLAR, A. B., 2010. VEGF in the lung: a role for novel isoforms: Am J Physiol Lung Cell Mol Physiol Am J Physiol Lung Cell Mol Physiol. 298(6), L768-74
WU, W. K., LLEWELLYN, O. P., BATES, D. O., NICHOLSON, L. B. and DICK, A. D., 2010. IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia: Immunobiology Immunobiology. 215(9-10), 796-803
BENEST, A. V. and BATES, D. O., 2009. Measurement of angiogenic phenotype by use of two-dimensional mesenteric angiogenesis assay: Methods Mol Biol Methods Mol Biol. 467, 251-70
BILLS, V. L., VARET, J., MILLAR, A., HARPER, S. J., SOOTHILL, P. W. and BATES, D. O., 2009. Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia: Clin Sci (Lond) Clin Sci (Lond). 116(3), 265-72
FOSTER, R. R., ZADEH, M. A., WELSH, G. I., SATCHELL, S. C., YE, Y., MATHIESON, P. W., BATES, D. O. and SALEEM, M. A., 2009. Flufenamic acid is a tool for investigating TRPC6-mediated calcium signalling in human conditionally immortalised podocytes and HEK293 cells: Cell Calcium Cell Calcium. 45(4), 384-90
QIU, Y., HOAREAU-AVEILLA, C., OLTEAN, S., HARPER, S. J. and BATES, D. O., 2009. The anti-angiogenic isoforms of VEGF in health and disease: Biochem Soc Trans Biochem Soc Trans. 37(Pt 6), 1207-13
RENNEL, E. S., HARPER, S. J. and BATES, D. O., 2009. Therapeutic potential of manipulating VEGF splice isoforms in oncology: Future Oncol Future Oncol. 5(5), 703-12
RENNEL, E. S., VAREY, A. H., CHURCHILL, A. J., WHEATLEY, E. R., STEWART, L., MATHER, S., BATES, D. O. and HARPER, S. J., 2009. VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo: Br J Cancer Br J Cancer. 101(7), 1183-93
SALMON, A. H., NEAL, C. R., SAGE, L. M., GLASS, C. A., HARPER, S. J. and BATES, D. O., 2009. Angiopoietin-1 alters microvascular permeability coefficients in vivo via modification of endothelial glycocalyx: Cardiovasc Res Cardiovasc Res. 83(1), 24-33
STONE, O. A., RICHER, C., EMANUELI, C., VAN WEEL, V., QUAX, P. H., KATARE, R., KRAENKEL, N., CAMPAGNOLO, P., BARCELOS, L. S., SIRAGUSA, M., SALA-NEWBY, G. B., BALDESSARI, D., MIONE, M., VINCENT, M. P., BENEST, A. V., AL HAJ ZEN, A., GONZALEZ, J., BATES, D. O., ALHENC-GELAS, F. and MADEDDU, P., 2009. Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization: Arterioscler Thromb Vasc Biol Arterioscler Thromb Vasc Biol. 29(5), 657-64
WOOLARD, J., BEVAN, H. S., HARPER, S. J. and BATES, D. O., 2009. Molecular diversity of VEGF-A as a regulator of its biological activity: Microcirculation Microcirculation. 16(7), 572-92
NOWAK, D.G., WOOLARD, J., AMIN, E.M., KONOPATSKAYA, O., SALEEM, M.A., CHURCHILL, A.J., LADOMERY, M.R., HARPER, S.J. and BATES, D.O., 2008. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors Journal of Cell Science. 121(20), 3487-3495
RENNEL, E.S., WAINE, E., GUAN, H., SCHÜLER, Y., LEENDERS, W., WOOLARD, J., SUGIONO, M., GILLATT, D., KLEINERMAN, E.S., BATES, D.O. and HARPER, S.J., 2008. The endogenous anti-angiogenic VEGF isoform, VEGF₁₆₅b inhibits human tumour growth in mice British Journal of Cancer. 98(7), 1250-1257
VAREY, A. H. R., RENNEL, E. S., QIU, Y., BEVAN, H. S., PERRIN, R. M., RAFFY, S., DIXON, A. R., PARASKEVA, C., ZACCHEO, O., HASSAN, A. B., HARPER, S. J. and BATES, D. O., 2008. VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy BRITISH JOURNAL OF CANCER. 98(8), 1366-1379